- BioMark Diagnostics (BUX) has received an C$825,000 grant to develop its liquid biopsy assay for early-stage lung cancer screening
- The company’s subsidiary, BioMark Diagnostic Solutions, will perfect the assay under the guidance of Dr. Philippe Joubert
- The goal is to develop a low-cost, high-throughput test that makes early-stage lung cancer screening feasible and affordable for at-risk populations
- BioMark develops proprietary, non-invasive and accurate cancer diagnostic solutions
- BioMark Diagnostics (BUX) is down by 1.16 per cent and is currently trading at $0.425 per share
BioMark Diagnostics (BUX) has received an C$825,000 grant to develop its liquid biopsy assay for early-stage lung cancer screening.
The company’s subsidiary, BioMark Diagnostic Solutions, will perfect the assay under the guidance of Dr. Philippe Joubert and a team of leading clinicians, academic researchers and data scientists.
The overarching goal is to develop a low-cost, high-throughput test that makes early-stage lung cancer screening feasible and affordable for at-risk populations.
The two-year project will involve 1200 individual samples from the Institut Universitaire de Cardiologie et de Pneumologie de Québec – Université Laval’s Québec Respiratory Health Research Network site.
A majority of the funding is provided by the Consortium for Industrial Research and Innovation in Medical Technology (MEDTEQ+), the Spark grant from the Canadian Cancer Society, the Canadian Institutes of Health Research – Institute of Cancer Research, and Brain Canada Foundation.
Rashid Ahmed Bux, BioMark’s CEO, commented,
“This is an important project for BioMark as it gears up for the introduction of lung cancer biomarkers that can be incorporated into a screening program across Canada, beginning in Quebec, and later globally.”
BioMark develops proprietary, non-invasive and accurate cancer diagnostic solutions.
BioMark Diagnostics (BUX) is down by 1.16 per cent and is currently trading at $0.425 per share as of 10:27 am ET.